1-methyl-4-(pyridine-2-carbonyl)-piperazine | 39640-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-methyl-4-(pyridine-2-carbonyl)-piperazine
• 英文别名: (4-Methylpiperazin-1-yl)-pyridin-2-ylmethanone
• CAS: 39640-18-1
• 化学式: C₁₁H₁₅N₃O
• mdl: MFCD01415941
• 分子量: 205.26
• InChiKey: QZPSGFQPRPACRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  36.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-4-(pyridine-2-carbonyl)-piperazine 、 富马酸 以45%的产率得到
  参考文献：
  名称：

  BUDAI Z.; MEZEI T.; LAY A., ACTA CHIM. ACAD. SCI. HUNG., 1980, 105, NO 4, 241-246

  摘要：

  DOI：
• 作为产物：
  描述：

  吡啶-2-羧酸钾 以 四氢呋喃 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 1-methyl-4-(pyridine-2-carbonyl)-piperazine
  参考文献：
  名称：

  Budai, Z.; Mezei, T.; Lay, A., Acta Chimica Academiae Scientiarum Hungaricae, 1980, vol. <4> 105, p. 241 - 246

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017011776A1

  公开（公告）日：2017-01-19

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• [EN] ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013092574A1

  公开（公告）日：2013-06-27

  The present invention relates to substituted isothiazolo[5,4-b]pyridine-2-carboxamides of the formula I, in which R1, R2, R3, R10, R11 and X are as defined in the claims. The compounds of the formula I are inhibitors of transglutaminases, in particular transglutaminase 2 (TGM2), and are suitable for the treatment of various diseases, for example degenerative joint diseases such as osteoarthritis. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代异噻唑并[5,4-b]吡啶-2-羧酰胺，其中R1、R2、R3、R10、R11和X如权利要求中所定义。式I的化合物是转谷氨酰胺酶抑制剂，特别是转谷氨酰胺酶2（TGM2）的抑制剂，并适用于治疗各种疾病，例如退行性关节疾病如骨关节炎。本发明还涉及制备式I的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRAZINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018136661A1

  公开（公告）日：2018-07-26

  Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了Formula I的化合物及其立体异构体和药学上可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4在规范中给出的含义，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi

  公开号：US20140296169A1

  公开（公告）日：2014-10-02

  The present disclosure relates to substituted isothiazolo[5,4-b]pyridine-2-carboxamides of the formula I, in which R1, R2, R3, R10, R11 and X are as defined in the claims. The compounds of the formula I are inhibitors of transglutaminases, in particular transglutaminase 2 (TGM2), and are suitable for the treatment of various diseases, for example degenerative joint diseases such as osteoarthritis. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本公开涉及公式I的取代异噻唑并[5,4-b]吡啶-2-羧酰胺，其中R1、R2、R3、R10、R11和X如索赔中所定义。公式I的化合物是转谷氨酰胺酶抑制剂，特别是转谷氨酰胺酶2（TGM2）的抑制剂，并适用于治疗各种疾病，例如退行性关节疾病如骨关节炎。本发明还涉及公式I化合物的制备方法，它们作为药物的用途，以及包含它们的药物组合物。
• Rhodium-Catalyzed Reaction of N-Acylpiperazines with CO and Ethylene. Carbonylation at a C-H Bond Directed by an Amido Group
  作者：Yutaka Ishii、Naoto Chatani、Fumitoshi Kakiuchi、Shinji Murai

  DOI：10.1016/s0040-4039(97)01738-3

  日期：1997.10

  of N-acylpiperazines with CO (15 atm) and ethylene at 160 °C in the presence of Rh4(CO)12 results in dehydrogenation and carbonylation at a C-H bond. This reaction represents the first example of carbonylation at a C-H bond promoted by an oxygen functional group. © 1997 Elsevier Science Ltd.

  N-酰基哌嗪在160℃下在Rh 4（CO）12存在下与CO（15 atm）和乙烯反应，导致CH键处脱氢和羰基化。该反应代表由氧官能团促进的在CH键上羰基化的第一个例子。©1997爱思唯尔科学有限公司。